Introduction
============

Recently the travoprost 0.004%/timolol 0.5% fixed combination (DuoTrav^®^, Alcon Laboratories, Inc., Fort Worth, TX, USA) gained commercial approval for once daily dosing in the European Union. Barneby and associates showed that patients treated with the travoprost/timolol fixed combination, dosed each morning, had a greater reduction of intraocular pressure from baseline than timolol (1.9 to 3.3 mm Hg) or travoprost (0.9 to 2.4 mm Hg, \[dosed each evening\]) monotherapy.[@b1-opth-4-459]

An observational study, such as the design of the current trial, may provide additive findings to randomized controlled comparisons by assessing treatment effectiveness in routine clinical practice. Such designs have the potential advantage of analyzing larger, more diverse patient populations than randomized controlled trials. Observational studies might identify differences in effectiveness and safety among more therapeutic options.[@b2-opth-4-459],[@b3-opth-4-459]

The primary objective of this study was to assess the safety and efficacy of changing to travoprost/timolol fixed combination from other mono- or adjunctive (fixed or unfixed combinations) therapies.

Patients and methods
====================

Patients
--------

This study was a prospective, open-label, observational cohort in 19 clinical centers in Germany involving 22 investigators. Patients included were: aged at least 18 years; diagnosed with ocular hypertension, primary open-angle or pigment dispersion glaucoma in at least one eye (study eye); treated with either mono- or adjunctive therapy (in a fixed or unfixed combination) for a minimum of one week at Visit 1 (this time period was chosen because we believed few patients who needed further pressure reduction would gain much greater efficacy following a week or more of treatment that a physician would delay adding a second medicine); demonstrated a need for greater ocular hypotensive efficacy; the last dose of the previous medicine was instilled correctly so the patient was within the dosing cycle of their previous medication(s) at Visit 1; at Visit 1, had a pressure of between 19--35 mm Hg inclusive in at least one eye and ≤35 mm Hg in both eyes on monotherapy or between 19--32 mm Hg inclusive in at least one eye and ≤32 mm Hg in both eyes on adjunctive therapy; and had best-corrected visual acuity of 6/60 (20/200 Snellen, 1.0 logMAR) or better in each eye.

Excluded patients had: a presence of other primary or secondary glaucomas not listed in the inclusion criterion; presence of a narrow angle by gonioscopy not treated successfully by iridectomy; any abnormality preventing reliable applanation tonometry in study eye(s); corneal dystrophies; any opacity or patient uncooperativeness that restricted adequate examination of the ocular fundus or anterior chamber of the study eye(s); concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye; intraocular conventional surgery or laser surgery in study eye(s) less than 3 months prior to Visit 1; risk of visual field or visual acuity worsening as a consequence of participation in the trial; progressive retinal or optic nerve disease from any cause; women of childbearing potential not using reliable means of birth control; women who were pregnant or lactating; any clinically significant, serious, or severe medical or psychiatric condition; a condition which would present a special risk to the patient; participation in any other investigational study within 30 days prior to Visit 1; known medical history of allergy, hypersensitivity or poor tolerance to any components of the medications to be used in this trial; use of systemic medications known to affect the intraocular pressure which have not been on a stable course for at least 7 days prior to Visit 1 or an anticipated change in the dosage during the course of the study; reactive airway disease; sinus bradycardia (\<50 beats per minute); second- or third-degree atrioventricular block; overt cardiac failure; severe allergic rhinitis; unwillingness to risk the possibility of darkened irides or eyelash changes; a history of, or at risk for uveitis, cystoid macular edema or history of ocular herpes simplex.

Procedures
----------

Patients first signed an Ethics Committee-approved Informed Consent before any trial procedures were performed. This trial (NCT00519753) was registered at <http://www.clinicaltrials.gov/>. At each visit patients underwent Goldmann applanation tonometry and slit lamp biomicroscopy, and had Snellen visual acuity and adverse event assessments performed. Patients completed a symptom survey at Visits 1 and 3 and both patients and physicians provided a global preference response at Visit 3. At the end of Visit 1, qualified patients had their previous glaucoma therapy discontinued and received a commercially available open-label bottle of the travoprost/timolol fixed combination to be used once every evening in the study eye(s).

Patients returned at Week 4 for a safety visit (Visit 2). Visit 2 was scheduled at the same time (±1 hour) as Visit 1. Patients must have been taking travoprost/timolol fixed combination as prescribed or the visit was rescheduled. At this visit, patients received two additional bottles of the study medicine for use until the end of the study. Patients whose intraocular pressure was elevated over baseline (Visit 1), who were considered treatment failures to travoprost/timolol fixed combination, had an intolerable adverse event, or had been noncompliant to therapy, were discontinued from the trial.

Patients returned for the final visit at Week 12 (Visit 3) which was scheduled at the same time (±1 hour) as Visit 1. Patients must have been taking their travoprost/timolol fixed combination as prescribed or the visit was rescheduled. The patient's participation in the trial was considered successful if they completed the study (not discontinued due to noncompliance or an adverse event) and demonstrated a further reduction in intraocular pressure (≥1 mm Hg) from Visit 1. Patients withdrawn from the trial for protocol violations or medication errors were not included in the Per Protocol analysis.

Data analysis
-------------

The data were analyzed by PRN Pharmaceutical Research Network, LLC. All data analyses were two-sided and an α-level of 0.05 was used to declare statistical significance. An average eye, Per Protocol analysis was utilized. Internet- based electronic data capture was used for the trial.

The primary efficacy variable, the change in intraocular pressure between travoprost and the travoprost/timolol fixed combination based on Per Protocol dataset, was analyzed using a paired *t*-test within a one-way analysis of variance (ANOVA) test.[@b4-opth-4-459] A standard deviation of 2.8 mm Hg was assumed to determine the sample size calculation.[@b5-opth-4-459],[@b6-opth-4-459] This study provided an 80% power that a difference of 1.5 mm Hg could be excluded between the travoprost/timolol fixed combination and travoprost if at least 27 patients were analyzed for this subgroup.

The secondary efficacy variables: the change of intraocular pressure for the travoprost/timolol fixed combination from other therapeutic regimens (individual or group comparisons) also was analyzed using a paired *t*-test within an ANOVA. Only prior therapies with 27 or more patients who changed to the travoprost/timolol fixed combination were analyzed individually. This helped ensure a normal distribution of patients as well as a similar statistical power as the primary efficacy variable. For the change in pressure for the study cohort as a whole (from any previous therapy) to travoprost/timolol fixed combination, a one-way ANOVA was used.[@b4-opth-4-459] A paired *t*-test within an ANOVA test was also used to evaluate differences in the patient surveys and visual acuity between baseline (Visit 1) and Week 12 (Visit 3). As a result of multiple subgroup assessments (differing prior therapies), a modified Bonferroni correction (α/5) was used to adjust the *P*-value.[@b7-opth-4-459]

Adverse events were analyzed with a McNemar's test[@b6-opth-4-459] for intragroup analysis, and global preference by a *χ*^2^ or Fisher's exact test[@b4-opth-4-459] between travoprost/timolol fixed combination and prior therapy, as well as the study cohort as a whole.

Results
=======

Patients
--------

[Table 1](#t1-opth-4-459){ref-type="table"} describes the disposition of the patients who enrolled in the study and [Table 2](#t2-opth-4-459){ref-type="table"} details patient characteristics.

Intraocular pressure
--------------------

Intraocular pressure findings are presented in [Table 3](#t3-opth-4-459){ref-type="table"}. Significant decreases in intraocular pressure were observed from prior treatment (Visit 1, Day 0) with the travoprost/timolol fixed combination on the last exam (Visit 3, Month 3), from all prior mono- and adjunctive treatments, and from prior individual treatments that were analyzable with sufficient statistical power to be clinically meaningful, which included travoprost (primary efficacy variable), timolol, latanoprost, latanoprost/timolol fixed combination, brinzolamide. In addition, there was a significant improvement after changing from bimatoprost, but not bimatoprost/timolol fixed combination (*P* \< 0.001 and *P* = 0.696, respectively). [Figure 1](#f1-opth-4-459){ref-type="fig"} shows the intraocular pressure decrease from baseline (Visit 1), irrespective of prior therapy. At each prior intraocular pressure level, there was a further significant decrease in pressure after changing to travoprost/timolol fixed combination (*P* \< 0.001).

Safety
------

The most frequent adverse events are shown in [Table 4](#t4-opth-4-459){ref-type="table"}. In total, there were 93 (18%) patients with at least one ocular or systemic adverse event on travoprost/timolol fixed combination with hyperemia being most frequent (n = 37, 7%). There were 10 (2%) systemic adverse events with headache (n = 5, 1%) being most frequent.

Overall, 20 (4%) patients were discontinued for an adverse event. The most common adverse event resulting in a patient's discontinuation of the study was hyperemia (n = 6, 1%). There were three serious adverse events in patients, while on the travoprost/timolol fixed combination including, kidney stones (n = 1), dizziness (n = 1) and a fractured arm (n = 1). None of these serious events were believed to be related to the study medicine by the investigator.

Product preference and treatment success
----------------------------------------

[Table 5](#t5-opth-4-459){ref-type="table"} shows the preference by both the patient and doctor for either the travoprost/timolol fixed combination or the prior prescribed product. Both patients and doctors preferred the travoprost/timolol fixed combination to all prior treatments, both mono- and adjunctive treatments, and from common prior individual treatments.

[Table 6](#t6-opth-4-459){ref-type="table"} shows the results of the solicited symptom survey. Following the modified Bonferroni correction, there was a reduced incidence of ocular pain with the travoprost/timolol fixed combination (*P* = 0.01) and a reduction in eyelid crusting that was approaching significance (*P* = 0.08). Additionally, the prior medicine had a lower incidence of burning on instillation (*P* \< 0.001) although no patients discontinued their participation in the study due to this complaint.

Of patients initiating treatment, 93% (n = 484) were considered a treatment success by the definition provided in the methods section. Of patients changed from mono- and adjunctive therapy respectively, 94% (n = 364) and 90% (n = 121) were considered a success. From common individual therapies: travoprost, 90% (n = 46); timolol, 93% (n = 138); latanoprost, 92% (n = 59); the latanoprost/timolol fixed combination, 96% (n = 49); and brinzolamide, 97% (n = 32) were considered a success. There was not a statistical difference in success among the above individually considered treatment groups (*P* = 0.68).

Discussion
==========

The primary objective of this study was to assess the safety and efficacy of changing to travoprost/timolol fixed combination from other mono- or adjunctive (fixed or unfixed combinations) therapies.

This study showed significant decreases in intraocular pressure after 3 months of chronic dosing with the travoprost/timolol fixed combination from all common prior treatments analyzed as a group, both mono- and adjunctive treatments analyzed as a group, and from prior individual treatments that were analyzable with sufficient statistical power to be clinically meaningful, which included travoprost, timolol, latanoprost, latanoprost/timolol fixed combination and brinzolamide. The average decrease in pressure from all prior treatments was 5.6 mm Hg; the average reduction from all prior monotherapy and adjunctive therapy was 5.9 mm Hg and 4.5 mm Hg, respectively. Importantly, this significant decrease in intraocular pressure occurred from prior levels of pressure when the patient was already treated with ocular hypotensive therapy. In addition, there was a significant improvement after changing from bimatoprost, but not the bimatoprost/timolol fixed combination. However, only two patients were available in the latter group. The bimatoprost groups were analyzed because of the importance of this compound in the treatment of glaucoma. Furthermore, there was a significant decrease in pressure after changing to the travoprost/timolol fixed combination regardless of the pressure on common prior therapy (19 to \>26 mm Hg). This finding indicates the effectiveness of the travoprost/timolol fixed combination in further reducing intraocular pressure across a wide range of prior therapy.

One of the problems in analyzing data from a trial in which a prior therapy is changed to a switch therapy in an open-label fashion is that the switch therapy has an inherent advantage in intraocular pressure reduction. The reason for this is not known but may result from the 'regression to the mean' phenomenon.[@b8-opth-4-459] This occurs because even a treated intraocular pressure typically fluctuates within a certain range. Accordingly, if the intraocular pressure is measured by chance at the high end of its typical range, it may not have been a true worsening of the disease. Therefore, a physician may adjust a therapeutic regimen to decrease an intraocular pressure that appears too high. By the next clinic visit, if the intraocular pressure appears normalized, any change in therapy from the prior visit may only have appeared to have improved the pressure because it may have regressed towards its mean even on the previous therapeutic regimen.

Nevertheless, in this current trial, the extent of intraocular pressure reduction with the travoprost/timolol fixed combination from prior treatment was higher than expected. Prior studies with similar design (ie, an open-label fashion) have shown an average reduction of 3.6 mm Hg from adjunctive treatment and 3.4 mm Hg from monotherapy treatment, when switched to a fixed combination therapy.[@b8-opth-4-459]--[@b14-opth-4-459] Nonetheless, because of the unmasked, nonrandomized design of the current study design, further research is required to confirm the results of this study.

Safety results showed that the travoprost/timolol fixed combination was well tolerated in the majority of cases. In the Intention-to-Treat population, 4% of patients discontinued due to an adverse event, most commonly hyperemia (1%). An ocular or systemic adverse event occurred in 18% of patients, with the most common being hyperemia in 7% of patients. Systemic side effects were few, with the most frequent being headache at an incidence rate of 1%.

In total, 93% of patients were considered successfully treated with the travoprost/timolol fixed combination. The preference results showed a clear choice by both doctors and patients for the travoprost/timolol fixed combination. The reason for the strong preference for the fixed combination was not available in the product preference questionnaire. The preference choice may have been influenced by the positive results of the study, which showed that the travoprost based fixed combination appeared to have efficacy advantages, with a favorable safety profile, in comparison to prior therapies. Unfortunately, the results of the solicited patient survey failed to provide further clarity on why patients generally preferred the travoprost/timolol fixed combination. The survey results demonstrated that the travoprost/timolol fixed combination was associated with less ocular pain but also showed more burning and stinging with the fixed combination. There was a trend towards more patients, and their acquaintances, noticing more ocular redness on the travoprost/timolol fixed combination, but this was not significant after the Bonferroni correction for multiple comparisons.

The data generated from this study are clinically important because they indicate that when an ocular hypertensive or primary open-angle glaucoma patient, who was previously treated with one or two glaucoma agents, is in need of further intraocular pressure reduction, a physician can generally anticipate greater pressure reduction with a favorable safety profile, high patient preference and a low dropout rate, by changing to the travoprost/timolol fixed combination.

Conclusion
==========

This study suggests that changing patients from prior mono- or adjunctive therapy to the travoprost/timolol fixed combination can provide, on average, a further reduction in intraocular pressure while demonstrating a favorable safety profile and a high patient preference rate.

This study did not evaluate changing patients to the travoprost/timolol fixed combination in a masked, randomized, parallel comparative trial. Consequently our design may have produced potential bias in the results. In addition, this study did not explore the long-term clinical outcomes of using the travoprost/timolol fixed combination. Further research, with a more robust study design, is required to more fully understand the clinical profile of the travoprost/timolol fixed combination in treating primary open-angle glaucoma and ocular hypertension.
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###### 

Relevant population information -- Intention-to-Treat population

  **Population parameter**                                                  **Patients**   **Percent**
  ------------------------------------------------------------------------- -------------- -------------
  Intention-to-Treat population                                             522            100
  Per Protocol population                                                   474            91
  Subjects withdrawn for clinical reasons (more than one reason possible)   28             5
    Adverse events                                                          19             4
    Withdrew consent                                                        6              1
    Noncompliance                                                           2              0.4
    Lack of efficacy                                                        1              0.2
    Lost to followup                                                        1              0.2
    Other reasons                                                           4              1
  Subjects withdrawn for protocol deviations                                20             14
    Date of visit out of time frame                                         19             4
    Comedication not allowed Per Protocol                                   1              0.2

###### 

Patient characteristics -- Intention-to-Treat population

  **Characteristic**                     **Variable**                  **Patients**   **Percent**
  -------------------------------------- ----------------------------- -------------- -------------
  Gender                                 Female                        318            61
                                         Male                          204            39
  Race                                   Caucasian                     516            99
                                         Black                         4              1
                                         Asian                         1              0.2
                                         Hispanic                      1              0.2
  Iris color                             Blue                          248            48
                                         Brown                         155            30
                                         Green                         49             9
                                         Other                         70             13
  Age (years)                            ≤55                           70             13
                                         56--65                        123            24
                                         66--75                        196            38
                                         ≥76                           133            26
  Glaucoma diagnoses                     POAG                          471            90
                                         Ocular hypertension           43             8
                                         Pigmentary glaucoma           8              2
  Prior ophthalmic medication (n ≥ 30)   Timolol                       149            29
                                         Latanoprost                   64             12
                                         LTFC                          51             10
                                         Travoprost                    51             10
                                         Brinzolamide                  33             6
                                         Other                         174            33
  Past medical history (most common)     Arterial hypertension         205            39
                                         Diabetes                      101            19
                                         Thyroid                       49             9
                                         Lipid disorder                28             5
                                         Coronary artery disease       22             4
                                         Hematologic disorder          19             4
                                         Neurologic seizure disorder   18             3
  Concomitant medication (most common)   ACE inhibitor                 112            22
                                         Beta-blocker                  74             14
                                         Hormone therapy               77             15
                                         Antihyperglycemic             52             10
                                         Diuretic                      44             8

**Abbreviations:** POAG, primary open-angle glaucoma; LTFC, latanoprost/timolol fixed combination; ACE, angiotensin-converting enzyme.

###### 

Intraocular pressure at each study visit (by prior treatment) -- Per Protocol population mean \[mm Hg (standard deviation)\]

  **Treatment**      **Patients**   **Visit 1**   **Visit 2**   **Visit 3**    **V1--V3**   ***P*-value**
  ------------------ -------------- ------------- ------------- -------------- ------------ ---------------
  All                474            21.9 (2.1)    16.5 (2.2)    16.3 (2.2)     5.6 (2.6)    \<0.001
  Monotherapy        352            22.0 (2.2)    16.4 (2.2)    16.1 (1.9)     5.9 (2.4)    \<0.001
  Combined therapy   122            21.5 (2.0)    16.9 (2.3)    17.0 (2.9)     4.5 (2.8)    \<0.001
  Travoprost         45             22.1 (2.7)    16.2 (2.6)    15.8 (2.4)     6.3 (2.5)    \<0.001
  Timolol            130            21.8 (2.0)    16.4 (2.1)    16.1 (1.8)     5.7 (2.3)    \<0.001
  Latanoprost        60             22.3 (2.4)    16.7 (2.2)    16.0 (2.0)     6.3 (2.8)    \<0.001
  LTFC               47             21.5 (1.9)    17.6 (2.1)    17.1 (2.1)     4.4 (1.7)    \<0.001
  Brinzolamide       30             22.7 (2.4)    15.7 (2.5)    16.2 (2.3)     6.5 (2.8)    \<0.001
  Bimatoprost        16             22.4 (2.1)    16.1 (2.2)    16.3 (1.9)     6.2 (3.1)    \<0.001
  BTFC               2              20.8 (2.5)    16.0 (7.1)    17.0 (12.73)   3.8 (10.3)   0.70

**Notes:** The last two analyses were done despite the low number of patients because of the perceived importance of the clinical comparison.

**Abbreviations:** LTFC, latanoprost/timolol fixed combination; BTFC, bimatoprost/timolol fixed combination.

###### 

Ocular or systemic adverse events by prior therapy -- Intention-to-Treat population patients (%) (\>10 occurrences)

  **Adverse event**   **All**   **Monotherapy**   **Combined therapy**   **Travoprost**   **Timolol**   **Latanoprost**   **LTFC**   **Brinzolamide**
  ------------------- --------- ----------------- ---------------------- ---------------- ------------- ----------------- ---------- ------------------
  Patients            522       388               134                    51               149           64                51         33
  All                 93 (18)   65 (17)           28 (21)                9 (18)           33 (22)       5 (8)             3 (6)      4 (12)
    Mild              43 (8)    26 (7)            17 (13)                3 (6)            14 (9)        1 (2)             2 (4)      3 (9)
    Moderate          35 (7)    27 (7)            8 (6)                  4 (8)            15 (10)       3 (5)             1 (2)      0 (0)
    Severe            15 (3)    12 (3)            3 (2)                  2 (4)            4 (3)         1 (2)             0 (0)      1 (3)
  Hyperemia           37 (7)    23 (6)            14 (10)                1 (2)            10 (7)        1 (2)             0 (0)      2 (6)
  Ocular itching      13 (3)    10 (3)            3 (2)                  1 (2)            6 (4)         0 (0)             1 (2)      0 (0)

**Abbreviation:** LTFC, latanoprost/timolol fixed combination.

###### 

Patient and doctor's opinion about TTFC -- Per Protocol population

  **Treatment**      **Patients**   **Patient prefers TTFC**   **Doctor prefers TTFC**                   
  ------------------ -------------- -------------------------- ------------------------- ----- ---- ---- -----
  All                474            88                         86                        91    91   89   94
  Monotherapy        352            88                         85                        92    93   90   95
  Combined therapy   122            89                         83                        94    88   82   94
  Travoprost         45             93                         86                        100   93   86   100
  Timolol            130            85                         79                        92    91   86   96
  Latanoprost        60             90                         82                        98    97   92   100
  LTFC               47             85                         75                        96    83   72   94
  Brinzolamide       30             90                         77                        100   93   84   100
  Bimatoprost        16             75                         51                        99    88   69   100
  BTFC               2              100                        100                       100   50   0    100

**Abbreviations:** CI, confidence interval; TTFC, travoprost/timolol fixed combination; LTFC, latanoprost/timolol fixed combination; BTFC, bimatoprost/timolol fixed combination.

###### 

Ocular symptoms summary -- Per Protocol population patients (%)

                                                                                                             **Level**        **Visit 1**   **Visit 3**   ***P*-value**
  ---------------------------------------------------------------------------------------------------------- ---------------- ------------- ------------- ---------------
  Have you had dry eyes or dryness around your eyes since your last visit?                                   None             438 (92)      458 (97)      0.03
  Minimal                                                                                                    8 (2)            5 (1)                       
  Mild                                                                                                       16 (3)           8 (2)                       
  Moderate                                                                                                   11 (2)           2 (0.4)                     
  Severe                                                                                                     1 (0.2)          1 (0.2)                     
  Have you had pain in or around your eye when in the light since your last visit?                           None             465 (98)      471 (99)      0.01
  Minimal                                                                                                    3 (0.6)          0 (0)                       
  Mild                                                                                                       1 (0.2)          3 (0.6)                     
  Moderate                                                                                                   5 (1)            0 (0)                       
  Have your eyes teared more than normal since your last visit?                                              None             455 (96)      464 (98)      0.23
  Minimal                                                                                                    3 (0.6)          3 (0.6)                     
  Mild                                                                                                       8 (2)            5 (1)                       
  Moderate                                                                                                   6 (1)            2 (0.4)                     
  Severe                                                                                                     2 (0.4)          0 (0)                       
  Did your study eye drops sting or burn when you instilled them?                                            None             453 (96)      422 (89)      \<0.001
  Minimal                                                                                                    12 (3)           29 (6)                      
  Mild                                                                                                       7 (2)            4 (0.8)                     
  Moderate                                                                                                   2 (0.4)          19 (4)                      
  Have you had crusting around your eyes since your last visit?                                              None             458 (97)      467 (99)      0.08
  Minimal                                                                                                    9 (2)            6 (1)                       
  Mild                                                                                                       4 (0.8)          1 (0.2)                     
  Moderate                                                                                                   3 (0.6)          0 (0)                       
  Have you had itching of your eyes, eyelids, or the area around your eyes since your last visit?            None             445 (94)      441 (93)      0.93
  Minimal                                                                                                    15 (3)           14 (3)                      
  Mild                                                                                                       8 (2)            11 (2)                      
  Moderate                                                                                                   5 (1)            7 (2)                       
  Severe                                                                                                     1 (0.2)          1 (0.2)                     
  Since your last visit did you experience a sandy or gritty feeling after you instilled your study drops?   None             454 (96)      453 (96)      0.72
  Minimal                                                                                                    7 (2)            10 (2)                      
  Mild                                                                                                       9 (2%)           9 (2)                       
  Moderate                                                                                                   3 (0.6)          2 (0.4)                     
  Severe                                                                                                     1 (0.2)          0 (0)                       
  Have you had a feeling or irritation in your eyes since your last visit?                                   None             460 (97)      454 (96)      0.53
  Minimal                                                                                                    6 (1)            5 (1)                       
  Mild                                                                                                       5 (1)            9 (2)                       
  Moderate                                                                                                   3 (0.6)          5 (1)                       
  Severe                                                                                                     0 (0)            1 (0.2)                     
  Have you noticed redness in your study eye?                                                                None             458 (97)      439 (93)      0.03
  Minimal                                                                                                    3 (0.6)          11 (2)                      
  Mild                                                                                                       9 (2)            11 (2)                      
  Moderate                                                                                                   4 (0.8)          12 (3)                      
  Severe                                                                                                     0 (0)            1 (0.2)                     
  Have other people commented about redness in your study eye?                                               None             461 (97)      444 (94)      0.07
  Minimal                                                                                                    5 (1)            18 (2)                      
  Mild                                                                                                       3 (0.6)          10 (2)                      
  Moderate                                                                                                   5 (1)            11 (2)                      
  Severe                                                                                                     0 (0)            1 (0.2)                     
  How easy is it for you to get your eye drops in your study eye?                                            Very difficult   2 (0.4)       4 (0.8)       0.36
  Difficult                                                                                                  16 (3)           13 (3)                      
  Easy                                                                                                       335 (71)         355 (75)                    
  Very easy                                                                                                  121 (26)         102 (22)                    
